MedTrace Logo

Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer

NCT04551287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16164

Last updated 2023-08-08

No results posted yet for this study

Summary

Cervical cancer, the fourth most common cancer globally and the fourth leading cause of cancer-related deaths, can be effectively prevented through early screening. Detecting precancerous cervical lesions and halting their progression in a timely manner is crucial. However, accurate screening platforms for early detection of cervical cancer are needed. Therefore, it is urgent to develop an Artificial Intelligence Cervical Cancer Screening (AICS) system for diagnosing cervical cytology grades and cancer.

Conditions

  • Cervical Cancer
  • Diagnostic Platform
  • Diagnosing Cervical Cytology Grades and Cancer
  • Artificial Intelligence

Sponsors & Collaborators

  • Guangzhou Women and Children's Medical Center

    collaborator OTHER

  • The Third Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Herui Yao, PhD · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-12-14
Completion
2020-12-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04551287 on ClinicalTrials.gov